Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of cenobamate adjunctive therapy in primary generalized tonic-clonic seizures
2023-506688-32-00Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in generalized tonic-clonic seizure (GTCS), sponsored by SK Life Science, Inc. Primary endpoints: Incidence of adverse events and serious adverse events, Clinical laboratory test results and 3 more. Started May 2024; status: completed.
02
Drugs
cenobamate
03
Conditions
generalized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2023-506688-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506688-32-00.